drugset / Trial / NCT01443689
Allogenic Stem Cell Therapy in Patients With Acute Burn
Phase 1/2
Unknown
20 enrolled
Shenzhen Beike Bio-Technology Co., Ltd.
The Second Affiliated Hospital of Kunming Medical University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Burn trauma,especially extensive ones, remains a life-threatening local and general inflammatory condition destroying the skin and underlying tissues, and resulting in serious sequelae. Remarkable progress has been achieved during last 30 years,stem cell therapy plays an important role in this progress. Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for burn. In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation will be evaluated in patients with acute burn.
Timeline
- Start
- 2011-07
- Primary completion
- 2013-03
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human cord blood mononuclear cells | Cell therapy | — | — |
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | — | — |
Indications
No indication recorded.